Novavax expects Omicron-targeting vaccine by fourth quarter

Biotech company Novavax said it expects to be able to provide an Omicron-targeting vaccine in the fourth quarter of this year. Its vaccine is under FDA review.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.